Several other analysts also recently weighed in on MESO. Cantor Fitzgerald set a $23.00 price target on shares of Mesoblast and gave the company a buy rating in a research note on Thursday, August 30th. HC Wainwright set a $17.00 price target on shares of Mesoblast and gave the company a buy rating in a research note on Thursday, August 30th. Zacks Investment Research raised shares of Mesoblast from a hold rating to a buy rating and set a $6.75 price target for the company in a research note on Wednesday, September 19th. ValuEngine raised shares of Mesoblast from a hold rating to a buy rating in a research note on Wednesday, September 26th. Finally, TheStreet raised shares of Mesoblast from a d+ rating to a c- rating in a research note on Monday, October 1st. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $13.96.
Mesoblast stock opened at $4.13 on Thursday. The company has a current ratio of 3.57, a quick ratio of 3.57 and a debt-to-equity ratio of 0.12. Mesoblast has a fifty-two week low of $4.00 and a fifty-two week high of $8.78.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.